Sam Hong - Publications

Affiliations: 
2015 Rapafusyn Pharmaceuticals 

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Wang Y, Peng H, Guo Z, Ullman BR, Yamamoto K, Hong SY, Liu JO. Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1. Chemical Science. 12: 11484-11489. PMID 34667552 DOI: 10.1039/d1sc02295d  0.737
2019 Liu JO, Guo Z, Cheng Z, Wang J, Liu W, Peng H, Wang Y, Rao S, Li R, Ying X, Korangath P, Liberti M, Li Y, Xie Y, Hong S, et al. Discovery of a potent GLUT inhibitor using rapafucin 3D microarrays. Angewandte Chemie (International Ed. in English). PMID 31591797 DOI: 10.1002/Anie.201905578  0.626
2018 Guo Z, Hong SY, Wang J, Rehan S, Liu W, Peng H, Das M, Li W, Bhat S, Peiffer B, Ullman BR, Tse CM, Tarmakova Z, Schiene-Fischer C, Fischer G, et al. Rapamycin-inspired macrocycles with new target specificity. Nature Chemistry. PMID 30532015 DOI: 10.1038/S41557-018-0187-4  0.563
2017 Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, Li RJ, Shim JS, Liu JO. Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. Acs Chemical Biology. 12: 174-182. PMID 28103683 DOI: 10.1021/Acschembio.6B00849  0.656
2011 Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. Journal of Medicinal Chemistry. 54: 7751-8. PMID 22003962 DOI: 10.1021/Jm2004128  0.311
Show low-probability matches.